Progress in genomic analysis has resulted in the proposal that the intestinal microbiota is a crucial environmental factor in the development of multifactorial diseases,such as obesity,diabetes,rheumatoid arthritis,an...Progress in genomic analysis has resulted in the proposal that the intestinal microbiota is a crucial environmental factor in the development of multifactorial diseases,such as obesity,diabetes,rheumatoid arthritis,and inflammatory bowel diseases represented by Crohn’s disease and ulcerative colitis.Dysregulated gut microbiome contributes to the pathogenesis of such disorders;however,there are few effective treatments for controlling only disease-mediating bacteria.Here,we review current knowledge about the intestinal microbiome in health and disease,and discuss a regulatory strategy using a parenteral vaccine with emulsified curdlan and CpG oligodeoxynucleotides,which we have recently developed.Unlike other conventional injectable immunizations,our vaccine contributes to the induction of antigen-specific systemic and mucosal immunity.This vaccine strategy can prevent infectious diseases such as Streptococcus pneumoniae infection,and control metabolic symptoms mediated by intestinal bacteria(e.g.Clostridium ramosum)by induction of high titers of antigen-specific IgA at target mucosal sites.In the future,our vaccination approach could be an effective therapy for common infectious diseases and dysbiosis-related disorders that have been difficult to control so far.展开更多
基金Supported by the Ministry of Education,Culture,Sports,Science,and Technology of Japan(Grant-in-Aid for Early-Career Scientists),No. 19K17932 (To Fujimoto K)
文摘Progress in genomic analysis has resulted in the proposal that the intestinal microbiota is a crucial environmental factor in the development of multifactorial diseases,such as obesity,diabetes,rheumatoid arthritis,and inflammatory bowel diseases represented by Crohn’s disease and ulcerative colitis.Dysregulated gut microbiome contributes to the pathogenesis of such disorders;however,there are few effective treatments for controlling only disease-mediating bacteria.Here,we review current knowledge about the intestinal microbiome in health and disease,and discuss a regulatory strategy using a parenteral vaccine with emulsified curdlan and CpG oligodeoxynucleotides,which we have recently developed.Unlike other conventional injectable immunizations,our vaccine contributes to the induction of antigen-specific systemic and mucosal immunity.This vaccine strategy can prevent infectious diseases such as Streptococcus pneumoniae infection,and control metabolic symptoms mediated by intestinal bacteria(e.g.Clostridium ramosum)by induction of high titers of antigen-specific IgA at target mucosal sites.In the future,our vaccination approach could be an effective therapy for common infectious diseases and dysbiosis-related disorders that have been difficult to control so far.
